Discover
CADL
Candel Therapeutics, Inc.
9.88
2 x 7.75
2 x 12.92
bid
ask
-
0.42
4.08%
2 @ 04:00 PM
9.83 -0.05 (0.51%)
| Ytd | 74.87% | |
| 1y | 103.71% |
9.86
day range
10.87
4.35
52 week range
11.36
| Open | 10.27 | Prev Close | 10.30 | Low | 9.86 | High | 10.87 | Mkt Cap | 723.91M |
| Vol | 1.87M | Avg Vol | 2.08M | EPS | -1.01 | P/E | N/A | Forward P/E | -9.48 |
| Beta | -0.87 | Short Ratio | 7.72 | Inst. Own | 22.53% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 8.20 | 200-d Avg | 6.08 | 1yr Est | 19.00 |
CADL News
globenewswire.com
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEEDHAM, Mass., July 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company)
benzinga.com
Candel Therapeutics Starts Pivotal Phase 3 AURORA Study Of Aglatimagene Besadenovec Plus Valacyclov
Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical
globenewswire.com
Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimag
NEEDHAM, Mass., June 30, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company)
globenewswire.com
Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer
NEEDHAM, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company)
benzinga.com
Candel Therapeutics Announces Lancet Oncology Publication Of Phase 3 Data Showing 30% DFS Improvemen
Peer reviewed publication details pivotal data, demonstrating 30% improvement in disease-free surviv